On April 23, 2022, the Minister of Public Health, Hygiene, and Prevention announced a new case of Ebola virus disease (EVD) occurring in Mbandaka health zone in Equateur Province, Democratic Republic of the Congo (DRC). EVD outbreaks occurred previously in Equateur Province in 2018 and 2020. The 31-year-old male, a student from Boende in Tshuapa Province, returned to Mbandaka, Equateur Province on February 25, 2022. He was vaccinated against Ebola virus in 2020 and is not known to be an EVD
The health authorities in the Democratic Republic of the Congo today declared an outbreak of Ebola after a case was confirmed in Mbandaka, a city in the north-western Equateur Province. This is the third outbreak in the province since 2018. So far, just one case has been confirmed. The patient, a 31-year-old man, began experiencing symptoms on 5 April and after more than a week of care at home, sought treatment at a local health facility. On 21 April, the patient
Ebola vaccination of people at high risk kicked off today in Guinea as the emergency response was escalated to counter the spread of the virus that re-emerged in the country a little more than a week ago for the first time since 2016. The vaccination was launched in Gouecke, a rural community in N’Zerekore prefecture where the first cases were detected on 14 February. The Minister of Health and Public Hygiene of Guinea, General Remy Lamah, the United Nations Resident Coordinator,
The Ministry of Health of the Democratic Republic of the Congo (DRC) today announced that a new case of Ebola has been detected in Butembo, a city in North Kivu Province, where a previous outbreak was declared over in June 2020. The Butembo branch of the National Institute of Biomedical Research (INRB) confirmed Ebola in samples taken from a patient with Ebola-like symptoms who had sought treatment at a local health centre. The woman was the wife of an Ebola survivor.
The U.S. Food and Drug Administration has approved Ebanga (Ansuvimab-zykl), a human monoclonal antibody, for the treatment for Zaire ebolavirus (Ebolavirus) infection in adults and children. Ebanga blocks binding of the virus to the cell receptor, preventing its entry into the cell. FDA granted the approval to Ridgeback Biotherapeutics, LP. Ebanga was granted an Orphan Drug designation, which provides incentives to assist and encourage drug development for rare diseases. Additionally, the agency granted Ebanga a Breakthrough Therapy designation. “Patients who receive Ebanga should avoid